Syngene, Innate Pharmaceuticals to develop virulence blockers

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Biocon subsidiary Syngene International Pvt. Ltd. and Innate Pharmaceuticals AB will jointly develop, manufacture and market virulence blockers, a new class of drugs that could become an alternative to antibiotics, to counteract bacterial diarrhoeal disease.

Clinical studies of the therapeutic effect will be conducted over the next three years and a candidate drug will be developed to the stage of a limited phase 2 study in patients with diarrhoeal disease.

Once a therapeutic effect is demonstrated, Syngene will carry out further clinical studies enabling the virulence blocker to be registered as a drug for the treatment of bacterial diarrhoeal disease, the companies said.

Umea, Sweden-based Innate will have European marketing rights, while Bangalore, India-based Syngene will have rights to other parts of the world market. Each company will receive royalties on the sales conducted by the other.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.